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.2012.08.Abstract Objective: The study was designed to compare the efﬁcacy of dexmedetomidine whether
given intramuscular or intravenous for pediatric MRI sedation.
Subjects and methods: Ninety children between the ages of 2 and 8 years with ASA physical status
I–II, scheduled for elective MRI, were enrolled in a double blind, comparative randomized
study. Patients assigned into two equal groups. Group DV, sedation was performed using IV
dexmedetomidine hydrochloride; a loading dose of 1 lg/kg administered over 10 min followed by
a continuous infusion at 1 lg/kg/h. Group DM where the patient received IM dexmedetomidine
3 lg/kg. Primary endpoints included incidence of failed sedation and the requirement of midazolam
supplementation. Secondary endpoints were time to sedation, duration of sedation, discharge time,
and hemodynamic status.
Results: The sedation failure rate was signiﬁcantly higher in the DV group (40%) in comparison
with the DM group (20%) (P= 0.04). Also, the use of rescue midazolam was signiﬁcantly higher
in the VD group (0.37 ± 0.47 mg) in comparison to the DM group (0.17 ± 0.35 mg) (P= 0.025).
The onset of satisfactory sedation was signiﬁcantly shorter in DV group in comparison to DM
group (7.93 ± 0.884 vs. 16.87 ± 4.49). Also, the discharge time was signiﬁcantly less in the DV
group (32.27 ± 3.04 min) in comparison to DM group (41.87 ± 5.80 min). Patients in DV group
had signiﬁcantly lower MBP compared to patients in DM group after receiving dexmedetomidine
(p< 0.05). Although the HR decreased in both groups during the MRI study, the decrease was sta-
tistically signiﬁcant in the DV group compared to the DM group in the period extended from the
2nd to 35th min (p< 0.05).rtment of Anesthesia and Intensive Care, Suez Canal University Hospital, Egypt. Tel.: +2096599631041.
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48 T.F. Tammam, S.S. WahbaConclusion: In pediatric MRI sedation, although IM dexmedetomidine does have a late sedation
onset; it reduces the sedation failure rate, the need for supplement sedation and the incidence of
hemodynamic instability associated with IV dexmedetomidine.
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Dexmedetomidine is a potentially effective agent for sedation
during non-invasive procedures such as magnetic resonance
imaging (MRI) [1,2]. It has several potential beneﬁcial effects
over older sedatives including its fast onset of action, minimal
respiratory depression, and an option for repeated administra-
tion when needed for special procedures [3]. The risks of its
sedation are in part related to the inherently unpredictable re-
sponse to medication and to the route of administration. There
is a varied response in sedation to IV dexmedetomidine; it
should be titrated for successful sedation [2]. The needs for
titration are practically difﬁcult and interfere with the continu-
ity of MRI procedure. The most frequently seen adverse effects
of IV dexmedetomidine that has been reported are hypoten-
sion and bradycardia [4–7]. The ideal sedative should be
administer by a simple and non-sophisticated technique, and
produces adequate sedation conditions while minimizing the
incidence of adverse events. Intramuscular dexmedetomidine
administration might avoid the most serious risks and compli-
cations associated with IV dexmedetomidine and might reduce
the need for titration which is essential for IV sedation. The
study was designed to compare the efﬁcacy of dexmedetomi-
dine whether given Intramuscular or intravenous for pediatric
MRI sedation.
2. Patients and methods
After obtaining approval of the hospital’s Research Ethics
Committee and written informed consent from parents for
the sedation, 90 children between the ages of 2 and 7 years with
ASA physical status I–II, scheduled for elective MRI were en-
rolled in a double blind, comparative, randomized study. The
study was conducted from June 2009 to March 2012. Patients
with a history of cardiovascular, active respiratory tract, hepa-
tic, or renal diseases and by reason of parents’ refusal were ex-
cluded. Patient demographics, type of MRI study performed
and its imaging time, as well as patient’s ASA physical status
were recorded. Imaging time refers to the duration of imaging
study from initiation of scan till the radiologist conﬁrms com-
pletion of successful MRI study.
Patients were randomized to one of two groups for sedation:
In Group DV (n= 45), sedation was performed with dexmede-
tomidine hydrochloride (Precedex, Abbott, 200 lg/ml) intra-
venously, a loading dose of 1 lg/kg administered over 10 min,
followed by a continuous infusion at 1 lg/kg/h for the duration
of the procedure. In Group DM (n= 45), the dexmedetomi-
dine 3 lg/kg was delivered as a single IM injection in the lateral
cranial thigh muscle group; using a 25 gauge needle, with the
child on the parent’s knee or lying on the trolley 20 min before
the procedure. Every child had IM injection (dexmedetomi-
dine/saline) and IV infusion (dexmedetomidine/saline)
prepared by dedicated nurse, sedation was given by anesthesi-
ologists blinded to the group assignment. The patients wererandomly assigned on a one-to-one ratio. Randomization was
performed by means of a computer-generated random-
numbers table. Parents were instructed to make their children
NPO for solids 6 h and to give clear liquids up to 2 h prior to
their scheduled appointment. EMLA cream was applied 1 h
before the procedure to the places of IM injection and IV can-
nulation. Before each procedure, an IV access and standard
monitoring of electrocardiogram (ECG), non-invasive arterial
blood pressure (NIABP), and peripheral oxygen saturation
(SpO2), were established. Heart rate (HR) and rhythm were
displayed continuously by using a lead II ECG. All values of
vital signs (NIABP, HR, SPO2, and RR) were recorded every
2 min during the 1st 10 min and at 5-min intervals throughout
the procedure.
The sedation levels were consecutively assessed with
Ramsay sedation score (RSS) [8]. Primary endpoints included
incidence of failed Sedation and the requirement of midazolam
supplementation. Secondary endpoints were time to sedation,
duration of sedation, discharge time, and hemodynamic status.
The level of radiologist satisfaction regarding the quality of
sedation and the incidence of adverse events were also
recorded.
The time to sedation is deﬁned as the time in minutes (min)
from administration of sedative to achievement of adequate
sedation (RSS 4). Duration of sedation is deﬁned as the time
from onset to offset of sedation (RSS 2). Time to discharge
is the time from giving sedation to point at which patient meets
the discharge criteria (Alderete score of 8 or greater) [9]. The
sedation was classiﬁed as failed if RSS is less than 4 or if unac-
ceptable motion artifacts lead to inability to complete the
imaging study. Supplemental sedation was provided by using
titrated doses of midazolam IV 0.05 mg/kg every 4 min.
Adverse events, including airway complications, oxygen
desaturation less than 92%, emesis, and unplanned admission
were recorded. Bradycardia was identiﬁed as rates less than
60 beat min1 and was treated with IV atropine 20 lg/kg.
Hypotension was identiﬁed as a 20% decrease in the mean
blood pressure (SBP) and was treated with ﬂuids administra-
tion (10 ml/kg) and IV ephedrine 0.1 mg/kg. The need of head
repositioning, jaw thrust, and oral airway placement in a state
of airway obstruction were recorded. Radiologist satisfaction
was evaluated using a 10-cm visual analog scale (VAS) scores
(0, not satisﬁed and 10, totally satisﬁed) at the end of
procedure.
Statistical analyses: EPI-INFO program was used for sam-
ple size calculation by using incidence of sedation failure as the
primary outcome of this study. The a-error level was ﬁxed at
0.05 and power was set at 80% while the expected change to
be detected was 10%. Qualitative data were analyzed with
pearson Chi-square test. Quantitative data, expressed as
‘mean ± standard deviation (SD)’, were analyzed by one
way ANOVA test. A probability value of less than 0.05 was
considered statistically signiﬁcant. All analyses were done by
using the statistical package for social sciences (SPSS).
Table 1 Patient demographics and the clinical characteristics.
Parameters Group
Group DV (n= 45) Group DM (n= 45) Signiﬁcance (P value)
Age (yr) 3.70 ± 1.57 3.93 ± 1.46 NS
Weight (kg) 16.10 ± 3.57 15.70 ± 2.79 NS
ASA I/II 6/12 7/11 NS
Gender (F/M) 10/8 9/9 NS
Imaging time (min) 14.21 ± 3.4 14.86 ± 3.8 NS
Abbreviation: M; male, F; female, No; number as mean ± SD (M± SD).
Values are expressed as M± SD or absolute numbers.
NS = No signiﬁcant differences between the groups P> 0.05.
Table 2 The clinical outcome characteristics.
Parameters Group
Group DV (n= 45) Group DM (n= 45) Signiﬁcance (P value)
Onset of sedation 7.93 ± 0.88 16.87 ± 4.49 0.002
Duration of sedation 22.93 ± 2.31 24.27 ± 2.99 NS
Time to discharge 32.27 ± 3.04 41.87 ± 5.80 0.001
Sedation failure rate 18 (40%) 9 (20%) 0.04
Midazolam (mg) 0.37 ± 0.47 0.17 ± 0.35 0.025
Radiologist satisfaction (VAS) 7.10 ± 0.51 8.77 ± 0.74 0.001
Abbreviation: VAS; visual analog scale.
Values are expressed as M± SD or absolute numbers.
NS; P> 0.05.
Table 3 Type of MRI examination.
Type of MRI examination n (%) Group DV (n= 45) Group DM (n= 45) Signiﬁcance
Head or neck 27 29 NS
Spine 8 7 NS
Thorax 3 3 NS
Abdomen 4 3 NS
Extremity 3 3 NS
NS = P> 0.05.
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There was no signiﬁcant difference between the DM and DV
groups with respect to patient’s characteristics, type and
duration of the imaging study (p> 0.05, Tables 1 and 3).
The duration of MRI averaged 14.21 ± 3.4 min vs. 14.86 ±
3.8 min in DV group and DM group respectively. The onset
of satisfactory sedation was signiﬁcantly shorter in the DV
group in comparison with the DM group (7.93 ± 0.884 vs.
16.87 ± 4.49 min), Table 2. The patients in the DV group
had sedation duration of 22.93 ± 2.31 min, while it was
24.27 ± 2.99 min in the DM group with no signiﬁcance differ-
ence between them. On the contrary, the discharge time was
signiﬁcantly less in the DV group (32.27 ± 3.04 min) in com-
parison to the DM group (41.87 ± 5.80 min), Table 2.
Although all the patients completed the MRI studies, the
sedation failure rate was signiﬁcantly higher in the DV group
(40%) in comparison with the DM group (20%) (P= 0.04,
Table 2). Also, the use of rescue midazolam was signiﬁcantly
higher in the VD group (0.37 ± 0.47 mg) in comparison tothe DM group (0.17 ± 0.35 mg) (P= 0.025; Table 2). Regard-
ing using the dexmedetomidine as a sedative during the MRI
study in pediatrics, the radiologist satisfaction was signiﬁcantly
higher in the DM group in comparison to the DV group
(8.77 ± 0.74 vs. 7.10 ± 0.51) (P= 0.001; Table 2).
Patients in the DV group had signiﬁcantly lower MBP com-
pared to patients in DM group in the intervals extended from
the 6th to 20th min after receiving dexmedetomidine
(p< 0.05, Table 4). Although the HR decreased in both
groups during the MRI study, the decrease was statistically
signiﬁcant in the DV group compared to the DM group in
the intervals extended from the 4th to 35th min (p< 0.05,
Table 5).
During the MRI procedure, the incidence of bradycardia
and hypotension that led to intervention was higher in the
DV group (22.2% and 15.6% respectively) in comparison to
the DM group (6.67% and 6.67%); Table 6. All cases of bra-
dycardia and hypotension that have been reported were trea-
ted with IV atropine and ephedrine respectively in addition
to fast IV ﬂuid administration in case of hypotension. While
Table 4 Shows the mean blood pressure values of the two groups.
Time Group
Group DV (n= 45) Group DM (n= 45) Signiﬁcance
Baseline 63.20 ± 5.13 63.00 ± 4.54 NS
2 min 64.24 ± 4.45 62.50 ± 4.32 NS
4 min 61.20 ± 4.77 61.80 ± 3.68 NS
6 min 55.80 ± 5.27 61.27 ± 4.28 0.03
8 min 53.66 ± 4.12 60.60 ± 4.10 0.006
10 min 52.87 ± 2.83 58.73 ± 5.06 0.001
15 min 52.20 ± 3.23 55.73 ± 4.50 0.020
20 min 51.00 ± 3.76 55.33 ± 5.04 0.012
25 min 56.40 ± 3.58 57.73 ± 5.96 NS
35 min 58.20 ± 4.62 59.27 ± 5.06 NS
45 min 61.07 ± 4.20 60.73 ± 4.38 NS
Values are expressed as mean ± SD (M± SD).
NS = P> 0.05.
Table 5 Shows that the mean heart rate values of the two groups.
Time Group
Group DV (n= 45) Group DM (n= 45) Signiﬁcance (P value)
Baseline 100.00 ± 3.928 99.67 ± 4.25 NS
2 min 95.40 ± 4.26 99.20 ± 3.098 NS
4 min 84.60 ± 2.17 97.67 ± 3.498 0.001
6 min 84.20 ± 2.48 91.93 ± 4.65 0.001
8 min 84.07 ± 2.52 88.33 ± 4.07 0.002
10 min 80.13 ± 7.21 86.00 ± 3.93 0.010
15 min 79.53 ± 9.46 84.47 ± 7.49 NS
20 min 81.73 ± 2.92 85.60 ± 3.996 0.005
25 min 82.60 ± 2.75 85.13 ± 2.997 0.023
35 min 86.07 ± 3.15 89.87 ± 3.58 0.005
45 min 94.00 ± 4.26 95.53 ± 2.42 NS
Values are expressed as mean ± SD (M± SD).
NS = P> 0.05.
Table 6 Incidence of adverse events of the two groups.
Variables Group
Group DV (n= 45) Group DM (n= 45) Signiﬁcance (P value)
Bradycardia 10 (22.2%) 3 (6.67%) 0.037
Hypotension 7 (15.6%) 3 (6.67%) NS
Oxygen desaturations 3 (6.67%) 1 (2.2%) NS
Vomiting 2 (4.44%) 1 (2.2%) NS
NS = P> 0.05.
50 T.F. Tammam, S.S. Wahbathe incidence of Oxygen desaturation and vomiting was
(6.67% and 4.44%) in the DV group, it was (2.2% and
2.2%) in the DM group (p> 0.05, Table 6). In case of oxygen
desaturation, patients responded to head repositioning and as-
sisted mask ventilation.
4. Discussion
There are various possible uses of dexmedetomidine for
pediatric sedation, it appears to be a potentially effective
agent for sedation during non-invasive procedures [1,2].
Dexmedetomidine has several potential beneﬁcial effects asidefrom sedation, such as mild analgesia, anxiolysis, and its
minimal respiratory effects [1]. However, there are many unan-
swered questions directed towards the signiﬁcance of its side
effects and the wide varied sedative response to IV dexmede-
tomidine use in pediatrics. Mason et al. reported that only
9.7% of sedated patients using IV dexmedetomidine were able
to complete the CT imaging study during the loading dose
while 90.3% of patients required the maintenance infusion of
dexmedetomidine ± 2nd bolus dose [2]. Due to the regular
need for dose titration and the instant onset of adverse events,
patients may rapidly move from conscious sedation to deep
sedation with increased risk of cardiovascular instability, or
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one, with increased risk of unacceptable motion artifacts. Pa-
tients’ movement was noted to be a signiﬁcant problem on
using IV dexmedetomidine for pediatric sedation [10], the
addition of rescue of another sedative was necessary for
MRI rescanning. The sedative effect of dexmedetomidine is
dose-dependent, further dosing acts to lengthen the duration
of sedation and increase the risk of adverse effects [11]. For
MRI study, the ideal sedative should make by a non-
sophisticated method and produce adequate sedation
conditions while minimizing the incidence of adverse events.
In this study, IM dexmedetomidine had lower sedation fail-
ure rate and lesser adverse events, but had a signiﬁcantly delayed
onset of adequate sedation compared with IV dexmedetomi-
dine. Although the onset of sedation was shorter in IV dexmede-
tomidine, it is expected due to the route of drug administration.
Scheinin et al. have reported that time to maximal effect of IM
dexmedetomidine given to adult patients occurred between 60
and 150 min, depending on the dosage of dexmedetomidine
administered [12]. While IM dexmedetomidine had steady seda-
tion state and needed less rescue doses, the requirement for sup-
plemental sedation is essential for successful sedation in the IV
dexmedetomidine. IM dexmedetomidine may allow a ‘depot’ of
drug to be established such will be released gradually into the
systemic circulation over a period of time, allowing sound seda-
tion in children, reducing the possible adverse events and the
possible need for titration which is sensibly difﬁcult to practice
during theMRI procedure. Dexmedetomidine is a sedative with
limited experience in pediatric patients [2]. There are a limited
number of studies regarding using IM dexmedetomidine in
children. Mason et al. reported successful MRI on using IV
dexmedetomidine in 97.6% of children [13], and the cardiovas-
cular side- effects were seen in 16% of patients [13]. The most
common adverse effects experienced on using dexmedetomidine
are hypotension and bradycardia [6,7], while hypertension is
only frequent with the administration of the loading dose [7].
In our study, the mean arterial pressure values decreased when
using both IM and IV dexmedetomidine. However the mean
arterial pressure was signiﬁcantly lower after drug administra-
tion in the DV group, when compared with that of the DM
group. Also, there was higher incidence of hypotension and
bradycardia during IV dexmedetomidine administration in
comparison to IM dexmedetomidine. The hemodynamic
changes were steady in the IM dexmedetomidine in comparison
to the IV dexmedetomidine. The most frequently seen adverse
effects of IV dexmedetomidine that has been reported are
hypotension and bradycardia [5,7,9]. Dexmedetomidine has
been shown to produce dose-dependent decreases in blood pres-
sure and heart rate as a result of its alpha2 agonist effect on the
sympathetic ganglia with resulting sympatholytic effects [14].
Although IV dexmedetomidine was found effective for pediatric
non-invasive procedural sedation, statistically signiﬁcant
changes in hemodynamic state were reported [15]. It was ob-
served that the low doses of dexmedetomidine (0.25–1 lg kg1)
were associated with a decrease in MBP, while the higher doses
(1–4 lg kg1) of dexmedetomidine were reported to increase
transiently the MBP and decrease signiﬁcantly the HR [16,17].
On the other hand, at the most IM dexmedetomidine moder-
ately suppresses BP and HR depending on the dosage [12]. As
premedication, the IM dexmedetomidine produces mild hypo-
tension and bradycardia in patients undergoing arthroscopic
knee surgery [18]. In this study, the transient increase in MBPassociated with IV loading dose of dexmedetomidine might be
attributed to vascular smooth muscle constriction and direct
stimulation of peripheral alpha-receptors, likely alpha 1 [14].
This effect was not noted with the IM dexmedetomidine admin-
istration. The most common effect noted with alpha-2 agonists
is an initial hypertension, which results in a baroreceptor-
mediated reﬂex bradycardia. As the peripheral effects diminish,
central alpha-2 actions predominate, leading to decreased blood
pressure and cardiac output [14]. The incidence of vomiting and
peripheral oxygen desaturation was more noted with IV
dexmedetomidine administration as compared to IM dexmede-
tomidine. As evaluation of dexmedetomidine with respect to its
side effect proﬁle reveals that it is well tolerated [19,20]. Nausea,
discomfort and agitation noted as rare side effects observed
after dexmedetomidine administration [19,20]. Dexmedetomi-
dine can even decrease the need for antiemetics [21]. Also, the
effect of dexmedetomidine on the respiratory system is bare
minimum [22], which explains the comparable low incidence
of adverse respiratory events in the IV and IM dexmedetomi-
dine in the current study. Taghinia et al. [21] reported that
dexmedetomidine decreased the incidence of oxygen desatura-
tion and reduced the amounts of narcotic and anxiolytic
requirement. Similarly, Ebert et al. did not observe any apnea,
airway obstruction and hypoxemia with bolus doses of
dexmedetomidine [17]. Also, Belleville et al. [23] correlate the
irregular ventilation and apnea episodes with dexmedetomidine
1–2 lg kg1 administrated in 2 min, to the deep sedation, not to
the 2a adrenergic agonists which have no active role on the
respiratory center1 [17]. The radiologist satisfaction was signif-
icantly higher with the use of IM dexmedetomidine in pediatric
MRI sedation compared to IV dexmedetomidine. The IM
dexmedetomidine can reduce the most serious risks and
complications associated with IV dexmedetomidine and fre-
quent titration for sedation is not necessary. Although the study
encourages the use of IM dexmedetomidine in pediatric
sedation, the optimal dose and the concurrent use of IM
dexmedetomidine with other agents as dissociative agents needs
further study.
Conclusion, in pediatric MRI sedation, although IM dex-
medetomidine does have a late sedative onset; it reduces the
sedative failure rate, the need for supplement sedation and
the incidence of hemodynamic instability associated with IV
dexmedetomidine.References
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